-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB:MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Since its formation, Mindset has the goal of taking drug discovery from known psychedelics within the tryptamine drug class (such as psilocybin and DMT) to expand a portfolio of drug candidates for neuropsychiatric conditions.
This time, Mindset's scientists combined a fragment-based drug discovery (FBDD) method with a highly focused medicinal chemistry strategy to design and develop three new small molecule non-tryptamine scaffolds, introduced as Families 6, 7 and 8.
The company has already filed provisional patent applications on them. The new drug families include approximately forty novel drug-like lead compounds, which were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies.
Preclinical screening has shown a significant boost in receptor functional potency and selectivity and in the case of some compounds, a greater central nervous system (CNS) penetration, oral activity and efficacy.
CEO James Lanthier stated: "Mindset's leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field."
Photo by Matheus Ferrero on Unsplash
Mindset Pharma Inc. (OTCQB:MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Mindset Pharma Inc.(場外交易代碼:MSSTF), 一家生產精神疾病迷幻和非迷幻藥物的公司最近發現另外三個高度新穎的非色胺迷幻化合物家族。
Since its formation, Mindset has the goal of taking drug discovery from known psychedelics within the tryptamine drug class (such as psilocybin and DMT) to expand a portfolio of drug candidates for neuropsychiatric conditions.
自成立以來,Mindset的目標是從色胺類藥物(如裸蓋菇素和DMT)中獲得已知迷幻劑的藥物發現,以擴大其產品組合候選藥物治療神經精神疾病。
This time, Mindset's scientists combined a fragment-based drug discovery (FBDD) method with a highly focused medicinal chemistry strategy to design and develop three new small molecule non-tryptamine scaffolds, introduced as Families 6, 7 and 8.
這一次,Mindset的科學家將基於片段的藥物發現(FBDD)方法與高度集中的藥物化學策略相結合,設計和開發了三種新的小分子非色胺支架,介紹如下家庭6、7和8。
The company has already filed provisional patent applications on them. The new drug families include approximately forty novel drug-like lead compounds, which were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies.
該公司已經提交了臨時專利申請在他們身上。新的藥物家族包括大約40種新的類藥物先導化合物,它們是在體外羥色胺(5-HT)亞型受體和體外吸收、分佈、代謝和排泄(ADME)研究中合成和評價的。
Preclinical screening has shown a significant boost in receptor functional potency and selectivity and in the case of some compounds, a greater central nervous system (CNS) penetration, oral activity and efficacy.
臨牀前篩選顯示,受體功能效力和選擇性顯著提高,在某些化合物的情況下,更大的中樞神經系統(CNS)滲透、口服活動和療效。
CEO James Lanthier stated: "Mindset's leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field."
首席執行官詹姆斯·蘭蒂耶聲明説:“Mindset的領先藥物發現引擎繼續產生創新,有可能幫助世界各地患有神經精神和神經障礙的患者。新家族6、7和8的發現表明,我們致力於擴大我們的研發,並加強我們的知識產權(IP)組合,超越迷幻領域的經典色胺。”
Photo by Matheus Ferrero on Unsplash
馬修斯·費雷羅在Unspash上的照片
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧